Thalomid thalidomide: Phase II data; marketed to treat erythema nodosum leprosum in leprosy

University College London researchers presented data from 66 advanced cancer patients given 100 mg Thalomid per day until disease progression or unacceptable toxicity occurred. Partial responses were seen in 3 of 18 renal cancer patients. Disease stabilization was seen in 3 additional renal cancer patients, as well as in 4 of 17 melanoma patients. No other objective responses were seen. ...